EDM Serono S.A.

• Oncology: Developing and marketing treatments for various cancers, leveraging innovative approaches to target and destroy cancer cells while minimizing damage to healthy tissues. Specific details regarding their current oncology portfolio in the USA are available on the Merck KGaA website.

• Immunology: Addressing immune-related disorders through research and development efforts. Their work likely focuses on modulating the immune system to alleviate the symptoms and progress of diseases. Again, precise details on their US immunology portfolio are available through official Merck KGaA channels.

• Neurology: The development of treatments for neurological conditions, an area demanding significant innovation. This likely includes research into novel mechanisms for preventing or slowing the progression of neurodegenerative diseases. Information on specific US neurological projects is available through Merck KGaA's resources.

• Fertility: Historically a key area for EDM Serono, the legacy of their fertility treatments likely continues under Merck KGaA’s business operations. Details on current fertility-related offerings in the US market can be found on the parent company's site.

Corporate Structure and Global Presence:

Although operating under the Merck KGaA banner, EDM Serono's contributions to research, development and commercialization are integral to the parent company's overall success within the United States. The US operations are likely a significant part of their overall global strategy, aligning with Merck KGaA's broader commitment to delivering impactful therapies globally.

Note: To obtain the most current and detailed information on EDM Serono's specific activities and presence in the USA, consult the official Merck KGaA, Darmstadt, Germany website. This overview provides a general understanding based on the historical context of EDM Serono and its current alignment with Merck KGaA.